Molycorp Analyst Report Initiated by Recent Rise in PPS: Pullback on the Horizon Issued by BrokerBank Securities, Inc.
On February 17, 2015, the share price surged 12.01% to $1.09 in afternoon trading Tuesday as Chinese rare earth element prices climbed. The rare earth price index rose to 144 points on Monday, up 8.43% from the record low of 132.8 points in 2014. The rising of MCP is also due to an increase in production of the company's Mountain Pass facility. Molycorp's Mountain Pass California facility increased its rare earth production in the fourth quarter to nearly double the previous quarter.
After hitting its peak in 2011 at $74.22, Molycorp stock price has been losing most of its value and is currently traded at $1.06. Over the last two years, the stock has fallen from nearly $12 to as low as $0.28 in late January 2015. After being traded below $1 for more than 30 consecutive days, on January 30th, 2015, the company received a notice from the NYSE that the stock was in jeopardy of being delisted. MCP has also been one of the most highly shorted stocks on the NYSE. Despite the fact that currently there is no real catalyst for growth, a low trading price can be considered as a positive outlook as the stock is cheaper (in proportion to its earning) than other companies' in the industry.
For a more in-depth look at Molycorp with analysis of market trends and analyst recommendation please follow the link below. There is no cost obligation to view this report:
http://bit.ly/-MCP-AnalystReport
Copy and paste to browser may be required.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Not Financial Advice
BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
Source: BrokerBank Securities, Inc.
FA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.